Nebulized budesonide in asthma exacerbations: rules of therapy in the COVID-19 era


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The pandemic of the new coronavirus infection (COVID-19) has changed the attitude to the treatment of chronic lung diseases and especially bronchial asthma, when a change in the nature of respiratory symptoms will require a reasonable differential diagnosis between an asthma attack (asthmatic attack), exacerbation of asthma and COVID-19 infection. The currently existing «clinical dualism» of perception of an asthma patient is associated with the possibility of controlled asthma to reduce the risks of severe complications, and therefore have a «protective effect», while COVID-19 infection provokes «fatal» exacerbations in such patients. This distorted the practitioner's idea of an «asthma attack», an «asthma exacerbation», a coronavirus infection, making the differential diagnosis of these conditions difficult and poorly understood. The purpose of this review was to analyze the «rules of clinical therapy» and the use of «nebulized budesonide» in patients with bronchial asthma, taking into account real outpatient treatment opportunities and current recommendations.

Full Text

Restricted Access

About the authors

S. L Babak

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: sergbabak@mail.ru
107150, Moscow, 39/2 Losinoostrovskaya Str

M. V Gorbunova

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: mgorb@mail.ru
107150, Moscow, 39/2 Losinoostrovskaya Str

E. I Goruleva

Hospital of the Centrosojuz of the Russian Federation

Email: ekaterina.gorulyova@gmail.com
107150, Moscow, 39/1 Losinoostrovskaya Str

A. G Malyavin

A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia

Email: maliavin@mail.ru
107150, Moscow, 39/2 Losinoostrovskaya Str

References

  1. Jordan R.E., Adab P., Cheng K.K. Covid-19: Risk factors for severe disease and death. BMJ. 2020; 368: m1198. 2 https ://dx.doi.org/10.1136/bmj.m1198
  2. Lombardi C., Gani F., Berti A. et al. Asthma and COVID-19: A dangerous liaison? Asthma Res Pract. 2021; 7(1): 9 https://dx.doi.org/10.1186/s40733-021-00075-z
  3. Shah S.A., Quint J.K., Nwaru B.I., Sheikh A. Impact of COVID-19 national lockdown on asthma exacerbations: interrupted time-series analysis of English primary care data. Thorax. 2021; 76(9): 860-66. https://dx.doi.org/10.1136/thoraxjnl-2020-216512
  4. de Boer G., Braunstahl G.J., Hendriks R., Tramper-Stranders G. Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. BMJ Open Respir Res. 2021; 8(1): e000758. https://dx.doi.org/10.1136/bmjresp-2020-000758.
  5. Salciccioli J.D., She L., Tulchinsky A. et al. Effect of COVID-19 on asthma exacerbation. J Allergy Clin Immunol Pract. 2021; 9(7): 2896-99.e1. https://dx.doi.org/10.1016Zj.jaip.2021.04.038
  6. Fletcher M., van der Molen T., Lenney W. et al. Primary care management of asthma exacerbations or attacks: Impact of the COVID-19 pandemic. Adv Ther. 2022; 39(4): 1457-73. https://dx.doi.org/10.1007/s12325-022-02056-x.
  7. Kaye L., Theye B., Smeenk I. et al. Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020; 8(7): 2384-85. https://dx.doi.org/10.1016/j.jaip.2020.04.053.
  8. Ramey O.L., Silva Almodovar A., Nahata M.C. Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic. Ann Allergy Asthma Immunol. 2022; 128(5): 561-67.e1. https://dx.doi.org/10.1016/j.anai.2022.02.010.
  9. Wu X., Xu Y., Jin L. et al. Association of preexisting asthma and other allergic diseases with mortality in COVID-19 Patients: A systematic review and meta-analysis. Front Med (Lausanne). 2021; 8: 670744. https://dx.doi.org/10.3389/fmed.2021.670744.
  10. Hou H., Xu J., Li Y. et al. The association of asthma with COVID-19 mortality: An updated meta-analysis based on adjusted effect estimates. J Allergy Clin Immunol Pract. 2021; 9(11): 3944-68.e5. https://dx.doi.org/10.1016/j.jaip.2021.08.016.
  11. Primary Care Respiratory Society UK. PCRS pragmatic guidance. Diagnosing and managing asthma attacks and people with COPD presenting in crisis during the UK Covid 19 epidemic. 2020. URL: https://www.pcrs-uk.org/sites/pcrs-uk.org/files/resources/COVID19/PCRS-Covid-19-Pragmatic-Guidance-v4-07-May-2020.pdf (date of access - 11.06.2022).
  12. British Thoracic Society Advice for healthcare professionals treating people with asthma (adults) in relation to COVID-19. 2020. URL: https://www.brit-thoracic.org.uk/document-library/quality-improvement/covid-19/bts-advice-for-healthcare-professionals-treating-patients-with-asthma/(date of access - 11.06.2022).
  13. Global Initiative for Asthma (GINA). GINA guidance about COVID-19 and asthma. URL: https://ginasthma.org/wp-content/uploads/2021/03/21_03_30-GINA-COVID-19-and-asthma.pdf (date of access - 11.06.2022).
  14. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2021. URL: https://ginasthma.org/gina-reports/(date of access - 11.06.2022).
  15. Клинические рекомендации. Бронхиальная астма. Российское респираторное общество, Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России. 2021. Рубрикатор клинических рекомендаций Минздрава России. ID: 359. Доступ: https://cr.minzdrav.gov.ru/schema/359_2 (дата обращения - 11.06.2022). @@ Clinical guidelines. Bronchial asthma.Russian Respiratory Society, Russian Association of Allergists and Clinical Immunologists, Russian Union of Pediatricians. 2021.Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. ID: 359.URL: https://cr.minzdrav.gov.ru/schema/359_2 (date of access - 11.06.2022) (In Russ.).
  16. Jones K.A., Gibson P.G., Yorke J. et al. Attack, flare-up, or exacerbation? The terminology preferences of patients with severe asthma. J Asthma. 2021; 58(2): 141-50. https://dx.doi.org/10.1080/02770903.2019.1665064.
  17. Haughney J., Winders T.A., Holmes S. et al.; PRECISION Improve Access to Better Care Task Force. Global Quality Standard for Identification and Management of Severe Asthma. Adv Ther. 2020; 37(9): 3645-59. https://dx.doi.org/10.1007/s12325-020-01450-7.
  18. Kerkhof M., Tran T.N., Allehebi R. et al. Asthma phenotyping in primary care: Applying the International Severe Asthma Registry Eosinophil Phenotype Algorithm across all asthma severities. J Allergy Clin Immunol Pract. 2021; 9(12): 4353-70. https://dx.doi.org/10.1016/j.jaip.2021.07.056
  19. Reddel H.K., Taylor D.R., Bateman E.D. et al.; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180(1): 59-99. https://dx.doi.org/10.1164/rccm.200801-060ST.
  20. Castillo J.R., Peters S.P., Busse W.W. Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017; 5(4): 918-27. https://dx.doi.org/10.1016/j.jaip.2017.05.001.
  21. Ong K.Y., Tan T.L., Chan A.K.W. et al. Managing asthma in the COVID-19 pandemic and current recommendations from professional bodies: A review. J Asthma. 2021; 58(11): 1536-43. https://dx.doi.org/10.1080/02770903.2020.1804578.
  22. Heikkinen T., Jarvinen A. The common cold. Lancet. 2003; 361(9351): 51-59. https://dx.doi.org/10.1016/S0140-6736(03)12162-9.
  23. Abrams E.M., Szefler S.J. Managing asthma during coronavirus disease-2019: An example for other chronic conditions in children and adolescents. J Pediatr. 2020; 222: 221-26. https://dx.doi.org/10.1016/j.jpeds.2020.04.049.
  24. Halpin D.M.G., Singh D., Hadfield R.M. Inhaled corticosteroids and COVID-19: A systematic review and clinical perspective. Eur Respir J. 2020; 55(5): 2001009. https://dx.doi.org/10.1183/13993003.01009-2020.
  25. Amir Najim Abood H.A., Al-Musawi Z.M., Hussein A.M., Hameed R.M. Effects of nebulized budesonide plus salbutamol and nebulized salbutamol monotherapy on mild to moderate acute exacerbation of asthma in children: A comparative study. J Pak Med Assoc. 2021; 71(Suppl 9) (12): S29-S34.
  26. Alangari A.A. Genomic and non-genomic actions of glucocorticoids in asthma. Ann Thorac Med. 2010; 5(3): 133-39. https://dx.doi.org/10.4103/1817-1737.65040.
  27. Panettieri R.A., Schaafsma D., Amrani Y. et al. Non-genomic effects of glucocorticoids: An updated view. Trends Pharmacol Sci. 2019; 40(1): 38-49. https://dx.doi.org/10.1016/j.tips.2018.11.002.
  28. Miller-Larsson A., Mattsson H., Hjertberg E. et al. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos. 1998; 26(7): 623-30.
  29. Терехова Е.П., Бодня О.С., Терехов Д.В., Ненашева Н.М. Возможности небулайзерной терапии бронхиальной астмы. Эффективная фармакотерапия. 2018; 6: 30-39. @@ Terekhova Ye.P., Bodnya O.S., Terekhov D.V., Nenasheva N.M. Possibilities of bronchial asthma nebulizer therapy. Effektivnaya farmakoterapiya = Effective Pharmacotherapy. 2018; 6: 30-39 (In Russ.)
  30. Saito M., Kikuchi Y., Kawarai Lefor A., Hoshina M. High-dose nebulized budesonide is effective for mild asthma exacerbations in children under 3 years of age. Eur Ann Allergy Clin Immunol. 2017; 49(1): 22-27.
  31. Wilson A.M., McFarlane L.C., Lipworth B.J. Systemic bioactivity profiles of oral prednisolone and nebulized budesonide in adult asthmatics. Chest. 1998; 114(4): 1022-27. https://dx.doi.org/10.1378/chest.114.4.1022.
  32. Arulparithi C.S., Babu T.A., Ravichandran C. et al. Efficacy of nebulised budesonide versus oral prednisolone in acute severe asthma. Indian J Pediatr. 2015; 82(4): 328-32. https://dx.doi.org/10.1007/s12098-014-1498-0.
  33. Ito K., Kanemitsu Y., Fukumitsu K. et al. The impact of budesonide inhalation suspension for asthma hospitalization: In terms of length of stay, recovery time from symptoms, and hospitalization costs. Allergol Int. 2020; 69(4): 571-77. https://dx.doi.org/10.1016/j.alit.2020.04.003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies